Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-272 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose | EXPERIMENTAL | Participants will be randomized to receive a single dose of VX-272. |
| Placebo: Part A | PLACEBO_COMPARATOR | Participants will be randomized to receive a single dose of placebo matched to VX-272. |
| Part B: Multiple Ascending Dose | EXPERIMENTAL | Participants will be randomized to receive multiple doses of VX-272. |
| Placebo: Part B | PLACEBO_COMPARATOR | Participants will be randomized to receive multiple doses of placebo matched to VX-272. |
| Part C: VX-272 in Combination With Tezacaftor (TEZ)/ Deutivacaftor (D-IVA) or D-IVA | EXPERIMENTAL | Participants will be randomized to receive VX-272 in combination with TEZ/D-IVA or D-IVA. |
| Placebo: Part C | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-272 in combination with TEZ/D-IVA or D-IVA. |
| Name | Type | Description |
|---|---|---|
| VX-272 | DRUG | Suspension for Oral Administration. |
| Placebo | DRUG | Suspension for Oral Administration. |
| Tezacaftor | DRUG | Tablet for oral administration. |
| Deutivacaftor | DRUG | Tablet for oral administration. |
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2) * A total body weight of more than (\>) 50 kg * Male and Female participants of non-childbearing potential Key Exclusion Criteria: * History of febrile illness or other acute illness that has not f...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | Alyftrek, Trikafta, Ivacaftor, VX-581, VX-272 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Roivant Sciences Ltd. | ROIV | 1 | PHASE1 | SP-101 |
VX-272 is an investigational small molecule being developed by Vertex Pharmaceuticals for cystic fibrosis. It is currently in Phase 1 clinical development and is designed to target the CFTR protein. It has not been approved by the FDA and remains an experimental therapy under study.
VX-272 is being studied for the treatment of cystic fibrosis, a respiratory condition. Development is at the Phase 1 stage, so its use remains investigational. The clinical program is evaluating the drug in a dose escalation study rather than in an approved treatment setting.
VX-272 targets CFTR, the cystic fibrosis transmembrane conductance regulator protein. CFTR is the protein implicated in cystic fibrosis. By acting on this protein target, VX-272 is being developed as a small molecule therapeutic for the disease, though it remains in early clinical testing.
VX-272 is being developed by Vertex Pharmaceuticals Incorporated, which trades on the Nasdaq under the ticker VRTX. Vertex is the sponsor of the clinical program evaluating the drug in cystic fibrosis.
VX-272 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program is ongoing, with one active trial and no completed trials reported for this asset.
VX-272 is being evaluated in one active clinical trial, NCT07437105, titled a Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants. The Phase 1 study is recruiting, is placebo controlled and double blind, and is expected to enroll 160 participants in the United States.